Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentin Goede

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Haematologica|November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
British Journal of Haematology|November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemiaOthman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with ImmunochemotherapyMagdalena Klanova, Mikkel Z Oestergaard, Marek Trněný, et al.
Leukemia & Lymphoma|November 26, 2016
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)Tait D Shanafelt, Sameer A Parikh, Peter A Noseworthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Haematologica|November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
British Journal of Haematology|November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemiaOthman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with ImmunochemotherapyMagdalena Klanova, Mikkel Z Oestergaard, Marek Trněný, et al.
Leukemia & Lymphoma|November 26, 2016
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)Tait D Shanafelt, Sameer A Parikh, Peter A Noseworthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Pageof 6